Researchers at Oxford used a natural experiment to compare cardiovascular outcomes among people aged 60 and older who received shingles vaccination around the October 2017 U.S. approval of the recombinant vaccine Shingrix. The investigators exploited the abrupt switch from the older live vaccine, Zostavax, to Shingrix to reduce confounding from healthy‑user bias that can plague traditional observational studies.
The analysis drew on TriNetX electronic health records from roughly 72,000 vaccinated individuals across 60 health systems. TriNetX does not include people with public health insurance, a feature noted by the authors. Participants were split into two matched groups who received their shots in the six months before or the six months after Shingrix approval and were followed for outcomes over seven years.
Compared with recipients of Zostavax, those who received Shingrix had lower rates of a composite cardiovascular burden after seven years. The study reported a 9% lower overall burden defined as a combined outcome of coronary heart disease, heart failure, and stroke.
Individual outcome associations reported in the analysis included:
The relative reductions translated into an absolute difference of approximately 1% fewer cardiovascular events over the seven‑year follow‑up period.
Although the per-person benefit described in the study is relatively small, authors and external commentators noted the potential for meaningful public‑health impact because millions of older adults receive shingles vaccination. For example, even modest relative risk reductions could prevent a large number of cardiovascular events at the population level if the associations reflect causal effects.
The investigators emphasized that the observed effect sizes are modest on an individual basis and must be interpreted in the context of the study design and population.
The study authors and quoted experts offered possible explanations but acknowledged that mechanisms are speculative. Two broad hypotheses were discussed:
Better prevention of varicella‑zoster reactivation: The virus that causes chickenpox and shingles has been linked to heightened cardiovascular risk in prior research. Superior protection from viral reactivation by Shingrix compared with Zostavax could reduce virus‑related cardiovascular events.
Vaccine‑induced immune modulation: Shingrix contains the adjuvant AS01, absent from Zostavax. Authors suggested the recombinant vaccine could trigger "trained immunity" or epigenetic changes in immune cells, alter cytokine profiles, and thereby modulate endothelial inflammation. These immune changes might influence atherosclerosis and vascular events by affecting the inflammatory processes that contribute to ischemic heart disease and vascular disease.
The article noted that previous natural experiments had not found cardiovascular benefits for Zostavax, which lends support to the hypothesis that properties specific to Shingrix (for example, its adjuvant) could be relevant.
Investigators were explicit about the observational nature of the findings despite the strengths of the natural experiment design. They stated that the study cannot establish causality. Key limitations reported in the article include reliance on electronic health records drawn from TriNetX, the exclusion of people with public insurance from that dataset, and the potential for residual confounding even with matching and the natural‑experiment approach.
Authors and outside experts in pharmacoepidemiology stressed the need for randomized controlled trials to determine whether the vaccine itself causes the reductions in cardiovascular outcomes.
The article referenced a large randomized trial in Denmark (DAN ZOSTER) that the authors said is enrolling roughly 162,000 people; first results were anticipated in 2027. The Oxford co‑authors and outside commentators framed that trial as a crucial test of causality.
If randomized trials confirm the associations, the implications could be substantial: Shingrix might be the first vaccine shown to protect both the heart and the brain, and even small individual benefits could translate into many prevented events at the population level. The authors and commentators called for further randomized studies to define which populations would benefit most and to clarify the underlying biological mechanisms.
In the interim, the investigators and commentators reiterated that the primary indication for shingles vaccination remains prevention of shingles and its complications, and any cardiovascular or neuroprotective benefits would be additional advantages that need confirmation in randomized data.